Trial Outcomes & Findings for Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors (NCT NCT04579757)

NCT ID: NCT04579757

Last Updated: 2025-05-08

Results Overview

According to National Cancer Institute Common Terminology Criteria for Adverse Events(AEs) version (v)5.0,DLT was defined as any of the following AEs during DLT observation period: Nonhematologic toxicities:grade 3 or higher nonhematologic toxicity, except for grade 3 fatigue lasting \<7 days, grade 3 rash returning to baseline or ≤grade 1 within 7 days with treatment, grade 3 hypertension downgraded to ≤grade 1 within 7 days with therapy, grade 3 endocrinopathy controlled by hormonal replacement with no hospitalization and resolving to ≤grade 1 within 7 days, grade 3 or higher amylase or lipase elevation without symptoms of pancreatitis, grade 3 nausea/vomiting or diarrhea for \<72 hours with care, grade 3 or higher electrolyte abnormality lasting up to 72 hours and resolving with treatment. Hematologic toxicities: grade 3 or higher febrile neutropenia, grade 4 neutropenia and grade 4 thrombocytopenia lasting \>7 days, grade 3 thrombocytopenia with severe bleeding, and grade 4 anemia.

• Recruitment status: TERMINATED
• Study phase: PHASE1/PHASE2
• Target enrollment: 87 participants
• Primary outcome timeframe: From the first dose of study drug (Day 1) up to Day 21 of Cycle 1 (cycle duration: 3 weeks)
• Results posted on: 2025-05-08

Participant Flow

This phase 1b/2, 2-part, open-label study was conducted in patients with advanced solid tumors.

The study consisted of a dose-escalation phase and a dose-expansion phase. A total of 12 patients in dose-escalation phase and 75 patients in dose-expansion phase were enrolled in this study. The study was terminated early based on the strategic re-evaluation of clinical development of surufatinib in the United States and Europe with no safety concerns. No patients were enrolled in Cohort E1 (alveolar soft part sarcoma) in the dose-expansion phase, hence this cohort is not presented in results.

Participant milestones

Measure	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 milligrams (mg) orally once daily (QD) in combination with tislelizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W) until progressive disease (PD), unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort A: CRC Patients with microsatellite stable, locally advanced or metastatic colorectal cancer (CRC) that was previously treated with at least 3 prior lines of therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B1: Thoracic NETs Patients with thoracic neuroendocrine tumor (NET) who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs Patients with gastroenteropancreatic (GEP) NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC Patients with locally advanced or metastatic small-cell lung cancer (SCLC) that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC Patients with microsatellite stable, programmed death-ligand 1 (PD-L1) ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (gastric cancer \[GC\]), and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS Patients with undifferentiated pleomorphic sarcoma (UPS) who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC Patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) and who had a B-Raf kinase V600E (BRAFV600E) mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Overall Study STARTED	6	6	15	10	20	15	3	9	3
Overall Study COMPLETED	0	0	0	0	1	0	0	1	0
Overall Study NOT COMPLETED	6	6	15	10	19	15	3	8	3

Reasons for withdrawal

Measure	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 milligrams (mg) orally once daily (QD) in combination with tislelizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W) until progressive disease (PD), unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort A: CRC Patients with microsatellite stable, locally advanced or metastatic colorectal cancer (CRC) that was previously treated with at least 3 prior lines of therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B1: Thoracic NETs Patients with thoracic neuroendocrine tumor (NET) who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs Patients with gastroenteropancreatic (GEP) NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC Patients with locally advanced or metastatic small-cell lung cancer (SCLC) that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC Patients with microsatellite stable, programmed death-ligand 1 (PD-L1) ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (gastric cancer \[GC\]), and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS Patients with undifferentiated pleomorphic sarcoma (UPS) who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC Patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) and who had a B-Raf kinase V600E (BRAFV600E) mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Overall Study Adverse Event	0	0	0	2	1	1	0	0	0
Overall Study Death	4	1	14	3	2	7	0	1	3
Overall Study Physician Decision	0	0	0	2	1	1	1	0	0
Overall Study Study Terminated By Sponsor	0	0	0	0	2	0	0	2	0
Overall Study Withdrawal by Subject	1	1	0	0	2	1	0	3	0
Overall Study Radiological or Clinical PD	1	4	1	3	9	4	2	2	0
Overall Study Start of New Therapy	0	0	0	0	2	1	0	0	0

Baseline Characteristics

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Baseline characteristics by cohort

Measure	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort A: CRC n=15 Participants Patients with microsatellite stable, locally advanced or metastatic CRC that was previously treated with at least 3 prior lines of therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B1: Thoracic NETs n=10 Participants Patients with thoracic NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs n=20 Participants Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC n=15 Participants Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC n=3 Participants Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS n=9 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=3 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Total n=87 Participants Total of all reporting groups
Age, Continuous	62.5 years STANDARD_DEVIATION 14.69 • n=5 Participants	68.2 years STANDARD_DEVIATION 9.83 • n=7 Participants	53.5 years STANDARD_DEVIATION 11.99 • n=5 Participants	58.6 years STANDARD_DEVIATION 9.70 • n=4 Participants	63.2 years STANDARD_DEVIATION 9.23 • n=21 Participants	58.1 years STANDARD_DEVIATION 14.27 • n=8 Participants	60.7 years STANDARD_DEVIATION 5.86 • n=8 Participants	59.9 years STANDARD_DEVIATION 13.94 • n=24 Participants	63.0 years STANDARD_DEVIATION 19.05 • n=42 Participants	60.0 years STANDARD_DEVIATION 12.11 • n=42 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	2 Participants n=7 Participants	8 Participants n=5 Participants	4 Participants n=4 Participants	10 Participants n=21 Participants	8 Participants n=8 Participants	0 Participants n=8 Participants	6 Participants n=24 Participants	1 Participants n=42 Participants	40 Participants n=42 Participants
Sex: Female, Male Male	5 Participants n=5 Participants	4 Participants n=7 Participants	7 Participants n=5 Participants	6 Participants n=4 Participants	10 Participants n=21 Participants	7 Participants n=8 Participants	3 Participants n=8 Participants	3 Participants n=24 Participants	2 Participants n=42 Participants	47 Participants n=42 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	2 Participants n=21 Participants	1 Participants n=8 Participants	0 Participants n=8 Participants	1 Participants n=24 Participants	0 Participants n=42 Participants	4 Participants n=42 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	5 Participants n=5 Participants	6 Participants n=7 Participants	15 Participants n=5 Participants	9 Participants n=4 Participants	18 Participants n=21 Participants	13 Participants n=8 Participants	3 Participants n=8 Participants	8 Participants n=24 Participants	2 Participants n=42 Participants	79 Participants n=42 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	1 Participants n=42 Participants	4 Participants n=42 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	1 Participants n=7 Participants	4 Participants n=5 Participants	0 Participants n=4 Participants	3 Participants n=21 Participants	1 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	9 Participants n=42 Participants
Race (NIH/OMB) White	3 Participants n=5 Participants	3 Participants n=7 Participants	10 Participants n=5 Participants	8 Participants n=4 Participants	17 Participants n=21 Participants	12 Participants n=8 Participants	3 Participants n=8 Participants	9 Participants n=24 Participants	3 Participants n=42 Participants	68 Participants n=42 Participants
Race (NIH/OMB) More than one race	1 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	3 Participants n=42 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	5 Participants n=42 Participants

PRIMARY outcome

Timeframe: From the first dose of study drug (Day 1) up to Day 21 of Cycle 1 (cycle duration: 3 weeks)

Population: The DLT-evaluable analysis set included all patients enrolled in dose escalation phase of the study who were evaluable for DLT assessment and received ≥85% of scheduled surufatinib and ≥67% of scheduled tislelizumab administration during the DLT assessment window and/or experienced a DLT.

According to National Cancer Institute Common Terminology Criteria for Adverse Events(AEs) version (v)5.0,DLT was defined as any of the following AEs during DLT observation period:

Nonhematologic toxicities:grade 3 or higher nonhematologic toxicity, except for grade 3 fatigue lasting <7 days, grade 3 rash returning to baseline or ≤grade 1 within 7 days with treatment, grade 3 hypertension downgraded to ≤grade 1 within 7 days with therapy, grade 3 endocrinopathy controlled by hormonal replacement with no hospitalization and resolving to ≤grade 1 within 7 days, grade 3 or higher amylase or lipase elevation without symptoms of pancreatitis, grade 3 nausea/vomiting or diarrhea for <72 hours with care, grade 3 or higher electrolyte abnormality lasting up to 72 hours and resolving with treatment. Hematologic toxicities: grade 3 or higher febrile neutropenia, grade 4 neutropenia and grade 4 thrombocytopenia lasting >7 days, grade 3 thrombocytopenia with severe bleeding, and grade 4 anemia.

Outcome measures

Measure	Dose Expansion Phase: Cohort E2: UPS Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Dose Escalation Phase: Number of Patients With Dose-Limiting Toxicities (DLTs)	—	—	1 Participants	2 Participants	—	—	—	—	—

PRIMARY outcome

Timeframe: From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months

Population: The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.

An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment in humans, whether or not considered related to the treatment. An AE was considered "serious" if, in the view of either the investigator or sponsor, it resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, was a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that started or worsened in severity on or after the first dose of study treatment and up to 30 days after the date of last study treatment administration.

Outcome measures

Measure	Dose Expansion Phase: Cohort E2: UPS Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Dose Escalation Phase: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Treatment Discontinuation Any TEAEs	—	—	6 Participants	6 Participants	—	—	—	—	—
Dose Escalation Phase: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Treatment Discontinuation Any TESAEs	—	—	5 Participants	3 Participants	—	—	—	—	—
Dose Escalation Phase: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Treatment Discontinuation Any TEAEs leading to surufatinib treatment discontinuation	—	—	3 Participants	0 Participants	—	—	—	—	—
Dose Escalation Phase: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Treatment Discontinuation Any TEAEs leading to tislelizumab treatment discontinuation	—	—	3 Participants	0 Participants	—	—	—	—	—

PRIMARY outcome

Timeframe: Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 37 months

Population: The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.

ORR was defined as the percentage of patients with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to <10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Outcome measures

Measure	Dose Expansion Phase: Cohort E2: UPS Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=15 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=10 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs n=20 Participants Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC n=15 Participants Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC n=3 Participants Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS n=9 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=3 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Dose Expansion Phase: Objective Response Rate (ORR)	—	—	6.7 percentage of patients Interval 0.2 to 31.9	0 percentage of patients NA indicates that upper and lower limits of confidence interval (CI) were not estimable as there were no patients with CR or PR in that disease cohort.	15.0 percentage of patients Interval 3.2 to 37.9	13.3 percentage of patients Interval 1.7 to 40.5	33.3 percentage of patients Interval 0.8 to 90.6	44.4 percentage of patients Interval 13.7 to 78.8	0 percentage of patients NA indicates that upper and lower limits of CI were not estimable as there were no patients with CR or PR in that disease cohort.

SECONDARY outcome

Timeframe: Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 42 months

Population: The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.

ORR was defined as the percentage of patients with a confirmed BOR of CR or PR as determined by the investigator using RECIST v1.1. BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Outcome measures

Measure	Dose Expansion Phase: Cohort E2: UPS Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Dose Escalation Phase: Objective Response Rate	—	—	0 percentage of patients NA indicates that upper and lower limits of CI were not estimable as there were no patients with CR or PR in that disease cohort.	0 percentage of patients NA indicates that upper and lower limits of CI were not estimable as there were no patients with CR or PR in that disease cohort.	—	—	—	—	—

SECONDARY outcome

Timeframe: Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 42 months

Population: The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.

PFS was defined as the time from the start of study treatment until the first radiographic documentation of objective progression as assessed by the investigator using RECIST v1.1, or death from any cause. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

Outcome measures

Measure	Dose Expansion Phase: Cohort E2: UPS n=9 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=3 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs n=15 Participants Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC n=10 Participants Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC n=20 Participants Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS n=15 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=3 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Dose Escalation and Dose Expansion Phases: Progression-free Survival (PFS)	NA months Interval 1.3 to NA indicates that median and upper limit of CI were not estimable due to insufficient number of patients with events at study closure.	2.8 months Interval 1.2 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	1.5 months Interval 1.2 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	6.0 months Interval 1.8 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	4.7 months Interval 2.7 to 5.4	4.5 months Interval 0.3 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	7.4 months Interval 3.1 to 20.0	1.4 months Interval 1.0 to 4.0	9.6 months Interval 5.6 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.

SECONDARY outcome

Timeframe: Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 42 months

Population: The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.

DCR was defined as the percentage of patients with a BOR of CR, PR, or stable disease (SD) lasting for at least 7 weeks as determined by the investigator using RECIST v1.1. BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.

Outcome measures

Measure	Dose Expansion Phase: Cohort E2: UPS n=9 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=3 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs n=15 Participants Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC n=10 Participants Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC n=20 Participants Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS n=15 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=3 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Dose Escalation and Dose Expansion Phases: Disease Control Rate (DCR)	55.6 percentage of patients Interval 21.2 to 86.3	33.3 percentage of patients Interval 0.8 to 90.6	0 percentage of patients NA indicates that upper and lower limits of CI were not estimable due to no patients with CR, PR, or SD for at least 7 weeks.	66.7 percentage of patients Interval 22.3 to 95.7	66.7 percentage of patients Interval 38.4 to 88.2	50.0 percentage of patients Interval 18.7 to 81.3	70.0 percentage of patients Interval 45.7 to 88.1	26.7 percentage of patients Interval 7.8 to 55.1	66.7 percentage of patients Interval 9.4 to 99.2

SECONDARY outcome

Timeframe: Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 42 months

Population: The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.

CBR was defined as the percentage of patients with a BOR of CR, PR, or durable SD as determined by the investigator using RECIST v1.1. Durable SD was SD for at least 6 months. BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.

Outcome measures

Measure	Dose Expansion Phase: Cohort E2: UPS n=9 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=3 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs n=15 Participants Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC n=10 Participants Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC n=20 Participants Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS n=15 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=3 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Dose Escalation and Dose Expansion Phases: Clinical Benefit Rate (CBR)	44.4 percentage of patients Interval 13.7 to 78.8	0 percentage of patients NA indicates that upper and lower limits of CI were not estimable due to no patients with CR, PR, or SD lasting for at least 6 months.	0 percentage of patients NA indicates that upper and lower limits of CI were not estimable due to no patients with CR, PR, or SD lasting for at least 6 months.	50.0 percentage of patients Interval 11.8 to 88.2	20.0 percentage of patients Interval 4.3 to 48.1	20.0 percentage of patients Interval 2.5 to 55.6	40.0 percentage of patients Interval 19.1 to 63.9	13.3 percentage of patients Interval 1.7 to 40.5	33.3 percentage of patients Interval 0.8 to 90.6

SECONDARY outcome

Timeframe: Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 42 months

Population: The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab. Only those patients with PR or CR (responders) were included in the analysis.

DoR was defined as the time from the first occurrence of PR or CR by RECIST v1.1, until PD or death, whichever came first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Outcome measures

Measure	Dose Expansion Phase: Cohort E2: UPS n=4 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs n=1 Participants Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC n=3 Participants Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS n=2 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=1 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Dose Escalation and Dose Expansion Phases: Duration of Response (DoR)	NA months NA indicates that median, upper and lower limits of CI were not estimable due to insufficient number of patients with events at study closure.	—	—	—	NA months NA indicates that median, upper and lower limits of CI were not estimable due to insufficient number of patients with events at study closure.	—	NA months Interval 15.0 to NA indicates that median and upper limit of CI were not estimable due to insufficient number of patients with events at study closure.	8.3 months Interval 5.8 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	11.0 months NA indicates that upper and lower limits of CI were not estimable due to insufficient number of patients with events at study closure.

SECONDARY outcome

Timeframe: Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 42 months

Population: The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab. Only those patients with PR or CR (responders) were included in the analysis.

TTR was defined as the time from start of study treatment until the date of first documented objective response, either CR or PR (whichever status was recorded first), according to RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Outcome measures

Measure	Dose Expansion Phase: Cohort E2: UPS n=4 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs n=1 Participants Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC n=3 Participants Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS n=2 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=1 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Dose Escalation and Dose Expansion Phases: Time to Response (TTR)	1.4 months Interval 1.2 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	—	—	—	2.7 months NA indicates that upper and lower limits of CI were not estimable due to insufficient number of patients with events at study closure.	—	3.9 months Interval 2.7 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	3.5 months Interval 1.3 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	2.7 months NA indicates that upper and lower limits of CI were not estimable due to insufficient number of patients with events at study closure.

SECONDARY outcome

Timeframe: Pre-dose on Day 1 of Cycles 1, 2, 5, 9, 17 and on Days 8 and 15 of Cycle 1; 2 to 4 hours post-dose on Days 1 and 15 of Cycle 1 (cycle duration: 3 weeks)

Population: The pharmacokinetic (PK) analysis set included all patients with at least 1 quantifiable concentration of surufatinib or tislelizumab. Only patients with data collected at specified timepoints are reported.

Blood samples were collected at the specified timepoints to determine plasma concentration of surufatinib.

Outcome measures

Measure	Dose Expansion Phase: Cohort E2: UPS n=9 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=2 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs n=15 Participants Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC n=10 Participants Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC n=19 Participants Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS n=15 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=3 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Dose Escalation and Dose Expansion Phases: Plasma Concentration of Surufatinib Cycle 1 Day 1: Pre-dose	NA nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that mean and standard deviation (SD) were not estimable as the values were below the lower limit of quantification (LLOQ) of 1.00 ng/mL.	NA nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that mean and standard deviation (SD) were not estimable as the values were below the lower limit of quantification (LLOQ) of 1.00 ng/mL.	NA nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that mean and standard deviation (SD) were not estimable as the values were below the lower limit of quantification (LLOQ) of 1.00 ng/mL.	NA nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that mean and standard deviation (SD) were not estimable as the values were below the lower limit of quantification (LLOQ) of 1.00 ng/mL.	NA nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that mean and standard deviation (SD) were not estimable as the values were below the lower limit of quantification (LLOQ) of 1.00 ng/mL.	NA nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that mean and standard deviation (SD) were not estimable as the values were below the lower limit of quantification (LLOQ) of 1.00 ng/mL.	NA nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that mean and standard deviation (SD) were not estimable as the values were below the lower limit of quantification (LLOQ) of 1.00 ng/mL.	NA nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that mean and standard deviation (SD) were not estimable as the values were below the lower limit of quantification (LLOQ) of 1.00 ng/mL.	NA nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that mean and standard deviation (SD) were not estimable as the values were below the lower limit of quantification (LLOQ) of 1.00 ng/mL.
Dose Escalation and Dose Expansion Phases: Plasma Concentration of Surufatinib Cycle 1 Day 1: 2 to 4 hours post-dose	275.64 nanograms per milliliter (ng/mL) Standard Deviation 165.937	782.50 nanograms per milliliter (ng/mL) Standard Deviation 463.155	293.03 nanograms per milliliter (ng/mL) Standard Deviation 244.593	576.00 nanograms per milliliter (ng/mL) Standard Deviation 415.108	426.62 nanograms per milliliter (ng/mL) Standard Deviation 312.209	276.36 nanograms per milliliter (ng/mL) Standard Deviation 243.080	294.13 nanograms per milliliter (ng/mL) Standard Deviation 292.335	406.97 nanograms per milliliter (ng/mL) Standard Deviation 212.791	506.27 nanograms per milliliter (ng/mL) Standard Deviation 653.616
Dose Escalation and Dose Expansion Phases: Plasma Concentration of Surufatinib Cycle 1 Day 8: Pre-dose	97.70 nanograms per milliliter (ng/mL) Standard Deviation 40.471	709.00 nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that SD was not estimable for 1 patient.	77.00 nanograms per milliliter (ng/mL) Standard Deviation 44.023	189.93 nanograms per milliliter (ng/mL) Standard Deviation 113.750	170.33 nanograms per milliliter (ng/mL) Standard Deviation 131.533	100.12 nanograms per milliliter (ng/mL) Standard Deviation 71.600	92.26 nanograms per milliliter (ng/mL) Standard Deviation 63.901	122.80 nanograms per milliliter (ng/mL) Standard Deviation 70.875	109.10 nanograms per milliliter (ng/mL) Standard Deviation 18.243
Dose Escalation and Dose Expansion Phases: Plasma Concentration of Surufatinib Cycle 1 Day 15: Pre-dose	118.92 nanograms per milliliter (ng/mL) Standard Deviation 75.457	—	64.36 nanograms per milliliter (ng/mL) Standard Deviation 15.246	181.56 nanograms per milliliter (ng/mL) Standard Deviation 125.156	135.96 nanograms per milliliter (ng/mL) Standard Deviation 83.673	159.00 nanograms per milliliter (ng/mL) Standard Deviation 139.802	84.95 nanograms per milliliter (ng/mL) Standard Deviation 70.121	96.79 nanograms per milliliter (ng/mL) Standard Deviation 43.933	111.05 nanograms per milliliter (ng/mL) Standard Deviation 19.728
Dose Escalation and Dose Expansion Phases: Plasma Concentration of Surufatinib Cycle 1 Day 15: 2 to 4 hours post-dose	518.00 nanograms per milliliter (ng/mL) Standard Deviation 302.182	—	318.67 nanograms per milliliter (ng/mL) Standard Deviation 146.770	757.33 nanograms per milliliter (ng/mL) Standard Deviation 498.399	657.54 nanograms per milliliter (ng/mL) Standard Deviation 369.146	354.25 nanograms per milliliter (ng/mL) Standard Deviation 52.519	471.78 nanograms per milliliter (ng/mL) Standard Deviation 330.598	425.75 nanograms per milliliter (ng/mL) Standard Deviation 235.698	188.00 nanograms per milliliter (ng/mL) Standard Deviation 41.012
Dose Escalation and Dose Expansion Phases: Plasma Concentration of Surufatinib Cycle 2 Day 1: Pre-dose	71.95 nanograms per milliliter (ng/mL) Standard Deviation 9.405	147.00 nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that SD was not estimable for 1 patient.	45.82 nanograms per milliliter (ng/mL) Standard Deviation 27.567	96.80 nanograms per milliliter (ng/mL) Standard Deviation 38.895	151.44 nanograms per milliliter (ng/mL) Standard Deviation 99.521	89.37 nanograms per milliliter (ng/mL) Standard Deviation 53.475	75.94 nanograms per milliliter (ng/mL) Standard Deviation 53.028	117.68 nanograms per milliliter (ng/mL) Standard Deviation 79.721	146.50 nanograms per milliliter (ng/mL) Standard Deviation 26.163
Dose Escalation and Dose Expansion Phases: Plasma Concentration of Surufatinib Cycle 5 Day 1: Pre-dose	—	—	—	55.25 nanograms per milliliter (ng/mL) Standard Deviation 8.132	141.20 nanograms per milliliter (ng/mL) Standard Deviation 117.885	41.00 nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that SD was not estimable for 1 patient.	61.08 nanograms per milliliter (ng/mL) Standard Deviation 22.279	105.70 nanograms per milliliter (ng/mL) Standard Deviation 54.164	—
Dose Escalation and Dose Expansion Phases: Plasma Concentration of Surufatinib Cycle 9 Day 1: Pre-dose	—	—	—	65.90 nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that SD was not estimable for 1 patient.	—	—	87.20 nanograms per milliliter (ng/mL) Standard Deviation 14.964	41.70 nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that SD was not estimable for 1 patient.	—
Dose Escalation and Dose Expansion Phases: Plasma Concentration of Surufatinib Cycle 17 Day 1: Pre-dose	—	—	—	—	—	—	85.10 nanograms per milliliter (ng/mL) Standard Deviation NA NA indicates that SD was not estimable for 1 patient.	—	—

SECONDARY outcome

Timeframe: Preinfusion on Day 1 of Cycles 1, 2, 5, 9, 17; end of infusion on Day 1 of Cycles 1 and 5; on Days 8 and 15 of Cycle 1 (cycle duration: 3 weeks)

Population: The PK analysis set included all patients with at least 1 quantifiable concentration of surufatinib or tislelizumab. Only patients with data collected at specified timepoints are reported.

Blood samples were collected at the specified timepoints to determine serum concentration of tislelizumab.

Outcome measures

Measure	Dose Expansion Phase: Cohort E2: UPS n=9 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=2 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs n=15 Participants Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC n=10 Participants Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC n=19 Participants Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS n=15 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=3 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Dose Escalation and Dose Expansion Phases: Serum Concentration of Tislelizumab Cycle 1 Day 1: Preinfusion	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable as the values were below the LLOQ of 400 ng/mL.	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable as the values were below the LLOQ of 400 ng/mL.	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable as the values were below the LLOQ of 400 ng/mL.	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable as the values were below the LLOQ of 400 ng/mL.	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable as the values were below the LLOQ of 400 ng/mL.	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable as the values were below the LLOQ of 400 ng/mL.	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable as the values were below the LLOQ of 400 ng/mL.	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable as the values were below the LLOQ of 400 ng/mL.	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable as the values were below the LLOQ of 400 ng/mL.
Dose Escalation and Dose Expansion Phases: Serum Concentration of Tislelizumab Cycle 1 Day 1: End of Infusion	55955.6 ng/mL Standard Deviation 15499.61	42200.0 ng/mL Standard Deviation 12727.92	44550.0 ng/mL Standard Deviation 7420.98	62750.0 ng/mL Standard Deviation 17420.53	57233.3 ng/mL Standard Deviation 8846.28	70990.0 ng/mL Standard Deviation 41600.73	61136.8 ng/mL Standard Deviation 15927.90	66220.0 ng/mL Standard Deviation 17336.43	67966.7 ng/mL Standard Deviation 45015.59
Dose Escalation and Dose Expansion Phases: Serum Concentration of Tislelizumab Cycle 1 Day 8	25475.0 ng/mL Standard Deviation 6549.10	16050.0 ng/mL Standard Deviation 1767.77	16980.0 ng/mL Standard Deviation 6850.75	26216.7 ng/mL Standard Deviation 7702.32	26446.2 ng/mL Standard Deviation 6387.83	29575.0 ng/mL Standard Deviation 5751.46	32244.4 ng/mL Standard Deviation 7253.58	35450.0 ng/mL Standard Deviation 8899.39	38233.3 ng/mL Standard Deviation 35800.33
Dose Escalation and Dose Expansion Phases: Serum Concentration of Tislelizumab Cycle 1 Day 15	19300.0 ng/mL Standard Deviation 4755.45	10940.0 ng/mL Standard Deviation 2489.02	14296.7 ng/mL Standard Deviation 5945.36	17900.0 ng/mL Standard Deviation 5297.55	17414.2 ng/mL Standard Deviation 4199.94	20571.4 ng/mL Standard Deviation 2817.63	24506.3 ng/mL Standard Deviation 6403.07	23783.3 ng/mL Standard Deviation 4274.20	43950.0 ng/mL Standard Deviation 40658.64
Dose Escalation and Dose Expansion Phases: Serum Concentration of Tislelizumab Cycle 2 Day 1: Preinfusion	12161.3 ng/mL Standard Deviation 4443.93	7640.0 ng/mL Standard Deviation 2729.43	9564.0 ng/mL Standard Deviation 7871.14	13804.0 ng/mL Standard Deviation 4782.16	13858.6 ng/mL Standard Deviation 4730.49	14033.3 ng/mL Standard Deviation 2436.12	18020.0 ng/mL Standard Deviation 5688.23	17725.0 ng/mL Standard Deviation 3860.55	38000.0 ng/mL Standard Deviation 36910.97
Dose Escalation and Dose Expansion Phases: Serum Concentration of Tislelizumab Cycle 5 Day 1: Preinfusion	19200.0 ng/mL Standard Deviation 3143.25	22700.0 ng/mL Standard Deviation NA NA indicates that SD was not estimable for 1 patient.	—	24400.0 ng/mL Standard Deviation 14028.90	36412.5 ng/mL Standard Deviation 34947.57	46400.0 ng/mL Standard Deviation NA NA indicates that SD was not estimable for 1 patient.	41575.0 ng/mL Standard Deviation 10065.32	31225.0 ng/mL Standard Deviation 12388.81	20100.0 ng/mL Standard Deviation NA NA indicates that SD was not estimable for 1 patient.
Dose Escalation and Dose Expansion Phases: Serum Concentration of Tislelizumab Cycle 5 Day 1: End of Infusion	103033.3 ng/mL Standard Deviation 17737.06	69000.0 ng/mL Standard Deviation NA NA indicates that SD was not estimable for 1 patient.	—	87166.7 ng/mL Standard Deviation 34425.04	102500.0 ng/mL Standard Deviation 26662.02	117500.0 ng/mL Standard Deviation 6363.96	113475.0 ng/mL Standard Deviation 16286.34	117550.0 ng/mL Standard Deviation 43800.65	80800.0 ng/mL Standard Deviation NA NA indicates that SD was not estimable for 1 patient.
Dose Escalation and Dose Expansion Phases: Serum Concentration of Tislelizumab Cycle 9 Day 1: Preinfusion	41100.0 ng/mL Standard Deviation 16970.56	—	—	22700.0 ng/mL Standard Deviation 4101.22	44800.0 ng/mL Standard Deviation NA NA indicates that SD was not estimable for 1 patient.	50000.0 ng/mL Standard Deviation NA NA indicates that SD was not estimable for 1 patient.	45500.0 ng/mL Standard Deviation 5384.24	41200.0 ng/mL Standard Deviation 24607.32	—
Dose Escalation and Dose Expansion Phases: Serum Concentration of Tislelizumab Cycle 17 Day 1: Preinfusion	47300.0 ng/mL Standard Deviation NA NA indicates that SD was not estimable for 1 patient.	—	—	—	—	41300.0 ng/mL Standard Deviation NA NA indicates that SD was not estimable for 1 patient.	44766.7 ng/mL Standard Deviation 12196.86	51900.0 ng/mL Standard Deviation NA NA indicates that SD was not estimable for 1 patient.	—

SECONDARY outcome

Timeframe: From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase

Population: The ADA analysis set included all patients who received at least 1 dose of tislelizumab and had a baseline and at least 1 post-baseline ADA result.

Blood samples were collected at the specified timepoints to detect ADAs to tislelizumab. Treatment-boosted ADA was defined as ADA positive at baseline that was boosted to a 4-fold or higher-level following treatment administration. Treatment-induced ADA was defined as ADA negative at baseline and ADA positive post-baseline.

Outcome measures

Measure	Dose Expansion Phase: Cohort E2: UPS n=9 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=2 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=6 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=5 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs n=14 Participants Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC n=8 Participants Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC n=16 Participants Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS n=13 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=2 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Dose Escalation and Dose Expansion Phases: Number of Patients With Antidrug Antibodies (ADA) to Tislelizumab Treatment-Boosted ADA	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Dose Escalation and Dose Expansion Phases: Number of Patients With Antidrug Antibodies (ADA) to Tislelizumab Treatment-Induced ADA	5 Participants	1 Participants	2 Participants	2 Participants	5 Participants	3 Participants	5 Participants	1 Participants	0 Participants

SECONDARY outcome

Timeframe: From the first dose of study treatment (Day 1) up to date of death due to any cause, up to approximately 42 months

Population: The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab. As pre-specified in the protocol and statistical analysis plan (SAP), OS was assessed only in Cohort A (CRC) and Cohort F (ATC) of the dose expansion phase.

OS was defined as the time from the start of study treatment until the date of death due to any cause.

Outcome measures

Measure	Dose Expansion Phase: Cohort E2: UPS Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=15 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=3 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Dose Expansion Phase (Cohorts A and F): Overall Survival (OS)	—	—	7.1 months Interval 4.8 to 11.8	5.3 months Interval 2.8 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	—	—	—	—	—

SECONDARY outcome

Timeframe: From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 33 months

Population: The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.

An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment in humans, whether or not considered related to the treatment. An AE was considered "serious" if, in the view of either the investigator or sponsor, it resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, was a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that started or worsened in severity on or after the first dose of study treatment and up to 30 days after the date of last study treatment administration.

Outcome measures

Measure	Dose Expansion Phase: Cohort E2: UPS Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=15 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=10 Participants Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs n=20 Participants Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC n=15 Participants Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC n=3 Participants Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS n=9 Participants Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=3 Participants Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Dose Expansion Phase: Number of Patients With Treatment-Emergent Adverse Events, Treatment-Emergent Serious Adverse Events and TEAEs Leading to Treatment Discontinuation Any TEAEs	—	—	14 Participants	10 Participants	20 Participants	15 Participants	3 Participants	9 Participants	3 Participants
Dose Expansion Phase: Number of Patients With Treatment-Emergent Adverse Events, Treatment-Emergent Serious Adverse Events and TEAEs Leading to Treatment Discontinuation Any TESAEs	—	—	9 Participants	5 Participants	9 Participants	8 Participants	0 Participants	4 Participants	1 Participants
Dose Expansion Phase: Number of Patients With Treatment-Emergent Adverse Events, Treatment-Emergent Serious Adverse Events and TEAEs Leading to Treatment Discontinuation Any TEAEs leading to surufatinib treatment discontinuation	—	—	3 Participants	2 Participants	5 Participants	5 Participants	0 Participants	2 Participants	0 Participants
Dose Expansion Phase: Number of Patients With Treatment-Emergent Adverse Events, Treatment-Emergent Serious Adverse Events and TEAEs Leading to Treatment Discontinuation Any TEAEs leading to tislelizumab treatment discontinuation	—	—	6 Participants	2 Participants	6 Participants	5 Participants	0 Participants	2 Participants	0 Participants

Adverse Events

Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab

Serious events: 5 serious events

Other events: 5 other events

Deaths: 4 deaths

Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab

Serious events: 3 serious events

Other events: 6 other events

Deaths: 1 deaths

Dose Expansion Phase: Cohort A: CRC

Serious events: 9 serious events

Other events: 14 other events

Deaths: 14 deaths

Dose Expansion Phase: Cohort B1: Thoracic NETs

Serious events: 5 serious events

Other events: 10 other events

Deaths: 4 deaths

Dose Expansion Phase: Cohort B2: GEP NETs

Serious events: 9 serious events

Other events: 20 other events

Deaths: 2 deaths

Dose Expansion Phase: Cohort C: SCLC

Serious events: 8 serious events

Other events: 15 other events

Deaths: 8 deaths

Dose Expansion Phase: Cohort D: GC

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Dose Expansion Phase: Cohort E2: UPS

Serious events: 4 serious events

Other events: 8 other events

Deaths: 1 deaths

Dose Expansion Phase: Cohort F: ATC

Serious events: 1 serious events

Other events: 3 other events

Deaths: 3 deaths

Serious adverse events

Measure	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=6 participants at risk Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=6 participants at risk Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort A: CRC n=15 participants at risk Patients with microsatellite stable, locally advanced or metastatic CRC that was previously treated with at least 3 prior lines of therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B1: Thoracic NETs n=10 participants at risk Patients with thoracic NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs n=20 participants at risk Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC n=15 participants at risk Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC n=3 participants at risk Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS n=9 participants at risk Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=3 participants at risk Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Musculoskeletal and connective tissue disorders Rhabdomyolysis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Abdominal pain	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Diarrhoea	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Nausea	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Vomiting	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Enteritis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Intestinal obstruction	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Intestinal perforation	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Large intestinal obstruction	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Obstruction gastric	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Pancreatic fistula	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Sepsis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Abdominal infection	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Cellulitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Clostridium difficile infection	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Sinusitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Urinary tract infection	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Disease progression	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Pyrexia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Asthenia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Chills	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Fatigue	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Gait disturbance	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Dehydration	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Cerebrovascular accident	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Dysarthria	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Hypertensive encephalopathy	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Neuropathy peripheral	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Seizure	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Syncope	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Cardiac disorders Atrial flutter	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Cardiac disorders Cardiac arrest	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Cardiac disorders Myocarditis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Cardiac disorders Pericardial effusion	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Cardiac disorders Ventricular fibrillation	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Hepatobiliary disorders Biliary dyskinesia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Hepatobiliary disorders Biliary obstruction	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Hepatobiliary disorders Cholecystitis acute	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Hepatobiliary disorders Hepatic failure	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Fistula	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Acute kidney injury	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Dyspnoea	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Injury, poisoning and procedural complications Fall	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Injury, poisoning and procedural complications Hand fracture	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Injury, poisoning and procedural complications Splenic rupture	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Injury, poisoning and procedural complications Subdural haematoma	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant neoplasm progression	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Vascular disorders Deep vein thrombosis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Vascular disorders Haematoma	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Vascular disorders Hypertension	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Blood and lymphatic system disorders Anaemia	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Angioedema	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Hyperhidrosis	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Ear and labyrinth disorders Vertigo	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Liver function test increased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Psychiatric disorders Delirium	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.

Other adverse events

Measure	Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab n=6 participants at risk Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 250 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab n=6 participants at risk Patients with advanced or metastatic solid tumors of any kind who had progressed on or were intolerant of standard therapies received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort A: CRC n=15 participants at risk Patients with microsatellite stable, locally advanced or metastatic CRC that was previously treated with at least 3 prior lines of therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B1: Thoracic NETs n=10 participants at risk Patients with thoracic NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort B2: GEP NETs n=20 participants at risk Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort C: SCLC n=15 participants at risk Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort D: GC n=3 participants at risk Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort E2: UPS n=9 participants at risk Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.	Dose Expansion Phase: Cohort F: ATC n=3 participants at risk Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.
Gastrointestinal disorders Nausea	50.0% 3/6 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	50.0% 3/6 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	66.7% 10/15 • Number of events 18 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	50.0% 5/10 • Number of events 10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	60.0% 12/20 • Number of events 17 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	40.0% 6/15 • Number of events 12 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	100.0% 3/3 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	44.4% 4/9 • Number of events 7 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Diarrhoea	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	50.0% 3/6 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	40.0% 6/15 • Number of events 14 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	30.0% 3/10 • Number of events 15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	55.0% 11/20 • Number of events 19 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	40.0% 6/15 • Number of events 8 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	100.0% 3/3 • Number of events 7 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	44.4% 4/9 • Number of events 16 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Vomiting	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	46.7% 7/15 • Number of events 13 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	30.0% 3/10 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	30.0% 6/20 • Number of events 10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	26.7% 4/15 • Number of events 6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 3/9 • Number of events 5 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Abdominal pain	33.3% 2/6 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 3/15 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	40.0% 4/10 • Number of events 8 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 4/20 • Number of events 6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 5/15 • Number of events 5 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	66.7% 2/3 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	22.2% 2/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Constipation	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 2/6 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 3/15 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 3/9 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	66.7% 2/3 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Flatulence	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Abdominal distension	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	15.0% 3/20 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Dry mouth	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	22.2% 2/9 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Stomatitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 3/15 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Dysphagia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Haematochezia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Ascites	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Dyspepsia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Gastrointestinal disorder	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Gingival bleeding	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Ileus	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Immune-mediated enterocolitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Large intestinal obstruction	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Mouth haemorrhage	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Odynophagia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Oral pain	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Pancreatitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Proctalgia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Fatigue	50.0% 3/6 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	50.0% 3/6 • Number of events 5 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	40.0% 6/15 • Number of events 9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	50.0% 5/10 • Number of events 11 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	55.0% 11/20 • Number of events 14 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	46.7% 7/15 • Number of events 8 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	100.0% 3/3 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	44.4% 4/9 • Number of events 6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Oedema peripheral	16.7% 1/6 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	35.0% 7/20 • Number of events 12 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 3/9 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Asthenia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 3/15 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	44.4% 4/9 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Pyrexia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	15.0% 3/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	22.2% 2/9 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Non-cardiac chest pain	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Chills	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	15.0% 3/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Localised oedema	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	66.7% 2/3 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Malaise	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Gait disturbance	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Pain	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Catheter site haematoma	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Catheter site haemorrhage	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Facial pain	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Influenza like illness	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Injection site pain	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Medical device site pain	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Mucosal inflammation	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Oedema	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Peripheral swelling	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
General disorders Xerosis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Decreased appetite	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	50.0% 3/6 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	60.0% 9/15 • Number of events 9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	40.0% 4/10 • Number of events 10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	55.0% 11/20 • Number of events 13 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 3/15 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	100.0% 3/3 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 3/9 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 5/15 • Number of events 8 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	25.0% 5/20 • Number of events 8 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	35.0% 7/20 • Number of events 36 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 3/15 • Number of events 7 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	26.7% 4/15 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	15.0% 3/20 • Number of events 7 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	26.7% 4/15 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 4/20 • Number of events 6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Dehydration	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	26.7% 4/15 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 3/15 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 8 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	25.0% 5/20 • Number of events 17 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	15.0% 3/20 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	15.0% 3/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hyperphosphataemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 4/20 • Number of events 11 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 4/20 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 4/20 • Number of events 6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Food intolerance	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Metabolism and nutrition disorders Hypertriglyceridaemia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Aspartate aminotransferase increased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	26.7% 4/15 • Number of events 7 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	30.0% 3/10 • Number of events 11 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	65.0% 13/20 • Number of events 37 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Alanine aminotransferase increased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 3/15 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	55.0% 11/20 • Number of events 26 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Blood creatinine increased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 2/6 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 5/15 • Number of events 7 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	35.0% 7/20 • Number of events 24 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Weight decreased	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	66.7% 4/6 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	26.7% 4/15 • Number of events 5 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 7 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	15.0% 3/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	66.7% 2/3 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Blood bilirubin increased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 3/15 • Number of events 5 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 5 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	30.0% 6/20 • Number of events 12 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Lymphocyte count decreased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 4/20 • Number of events 10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Lipase increased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	25.0% 5/20 • Number of events 16 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	66.7% 2/3 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Platelet count decreased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	26.7% 4/15 • Number of events 5 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	40.0% 4/10 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 4/20 • Number of events 9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Blood alkaline phosphatase increased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	25.0% 5/20 • Number of events 9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Blood lactate dehydrogenase increased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	30.0% 3/10 • Number of events 7 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 4/20 • Number of events 6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Amylase increased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 14 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	15.0% 3/20 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Blood creatine phosphokinase increased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	25.0% 5/20 • Number of events 7 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Electrocardiogram QT prolonged	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 4/20 • Number of events 6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Neutrophil count decreased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Activated partial thromboplastin time prolonged	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 8 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations White blood cell count decreased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Blood creatine increased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Ejection fraction decreased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Troponin T increased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Breath sounds abnormal	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Haemoglobin decreased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 5 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations Neutrophil count increased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Investigations White blood cell count increased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Vascular disorders Hypertension	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 2/6 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	66.7% 10/15 • Number of events 23 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	30.0% 3/10 • Number of events 7 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	45.0% 9/20 • Number of events 37 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	44.4% 4/9 • Number of events 8 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	66.7% 2/3 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Vascular disorders Flushing	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Vascular disorders Hypotension	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	15.0% 3/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Vascular disorders Orthostatic hypotension	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Vascular disorders Vasculitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Headache	33.3% 2/6 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	30.0% 6/20 • Number of events 7 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	26.7% 4/15 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 3/9 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Dizziness	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	30.0% 6/20 • Number of events 8 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Dysgeusia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	22.2% 2/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Paraesthesia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Tremor	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Hypoaesthesia	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Lethargy	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Neuropathy peripheral	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Sciatica	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Burning sensation	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Dysarthria	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Metabolic encephalopathy	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Sinus headache	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Somnolence	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Nervous system disorders Spinal cord compression	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 2/6 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	30.0% 3/10 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	25.0% 5/20 • Number of events 7 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 3/15 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	22.2% 2/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	50.0% 3/6 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	30.0% 3/10 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	15.0% 3/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 3/9 • Number of events 5 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Epistaxis	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Dysphonia	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	22.2% 2/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Sinus congestion	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Atelectasis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Pulmonary haemorrhage	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Sneezing	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Respiratory, thoracic and mediastinal disorders Sputum discoloured	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations COVID-19	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	15.0% 3/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Urinary tract infection	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	26.7% 4/15 • Number of events 6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Pneumonia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Upper respiratory tract infection	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Clostridium difficile infection	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Sinusitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Eye infection	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Abscess	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Bacteriuria	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Bronchitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Cellulitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Conjunctivitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Cystitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Folliculitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Gastrointestinal viral infection	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Herpes simplex	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Kidney infection	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Nasopharyngitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Pneumonia aspiration	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Rash pustular	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Respiratory tract infection	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Sepsis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Infections and infestations Skin infection	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Arthralgia	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	30.0% 3/10 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	40.0% 8/20 • Number of events 24 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Back pain	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	26.7% 4/15 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 4/20 • Number of events 7 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	22.2% 2/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 4/20 • Number of events 8 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	15.0% 3/20 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	15.0% 3/20 • Number of events 4 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Bursitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Muscle atrophy	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Musculoskeletal and connective tissue disorders Rheumatoid arthritis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	15.0% 3/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	22.2% 2/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Rash	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Decubitus ulcer	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Palmar-plantar erythrodysaesthesia syndrome	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Cold sweat	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Immune-mediated dermatitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Psoriasis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Skin and subcutaneous tissue disorders Skin lesion	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Proteinuria	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 2/6 • Number of events 6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 5/15 • Number of events 13 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	40.0% 4/10 • Number of events 5 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	45.0% 9/20 • Number of events 47 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Haematuria	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	25.0% 5/20 • Number of events 5 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Urinary retention	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Acute kidney injury	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Chronic kidney disease	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Dysuria	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Hydronephrosis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Leukocyturia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Micturition disorder	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Nephrolithiasis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Pollakiuria	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Renal pain	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Urinary tract pain	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Renal and urinary disorders Urine flow decreased	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Psychiatric disorders Confusional state	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 3/15 • Number of events 5 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Psychiatric disorders Insomnia	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Psychiatric disorders Anxiety	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Psychiatric disorders Depression	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Psychiatric disorders Depressed mood	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Psychiatric disorders Irritability	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Psychiatric disorders Panic attack	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Psychiatric disorders Restlessness	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Blood and lymphatic system disorders Anaemia	16.7% 1/6 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	30.0% 3/10 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 4/20 • Number of events 11 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	22.2% 2/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Blood and lymphatic system disorders Coagulopathy	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Blood and lymphatic system disorders Thrombocytosis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Cardiac disorders Sinus tachycardia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 2/6 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Cardiac disorders Tachycardia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Cardiac disorders Aortic valve disease	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Cardiac disorders Atrial fibrillation	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Endocrine disorders Hypothyroidism	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	13.3% 2/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Endocrine disorders Inappropriate antidiuretic hormone secretion	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Injury, poisoning and procedural complications Contusion	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Injury, poisoning and procedural complications Fall	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	11.1% 1/9 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Injury, poisoning and procedural complications Incision site discharge	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Injury, poisoning and procedural complications Postoperative wound complication	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Injury, poisoning and procedural complications Wound dehiscence	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Hepatobiliary disorders Immune-mediated hepatitis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	20.0% 2/10 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Hepatobiliary disorders Biliary obstruction	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Hepatobiliary disorders Hepatic artery thrombosis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Hepatobiliary disorders Hepatic cirrhosis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Eye disorders Vision blurred	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Eye disorders Vitreous floaters	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Ear and labyrinth disorders Hypoacusis	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Ear and labyrinth disorders Vertigo	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	16.7% 1/6 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Ear and labyrinth disorders Ear pruritus	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Reproductive system and breast disorders Pelvic pain	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	5.0% 1/20 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Reproductive system and breast disorders Gynaecomastia	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Reproductive system and breast disorders Vaginal haemorrhage	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Immune system disorders Seasonal allergy	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 2/20 • Number of events 2 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Immune system disorders Hypersensitivity	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	10.0% 1/10 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm skin	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	33.3% 1/3 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.
Product Issues Device occlusion	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/6 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	6.7% 1/15 • Number of events 1 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/10 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/20 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/15 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/9 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.	0.00% 0/3 • Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 9 months for dose escalation phase and approximately 33 months for dose expansion phase. All-cause mortality (deaths) were collected from signing of the informed consent form up to end of follow up, approximately 42 months. The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.

Additional Information

Nicky Murray

HUTCHMED Limited

Phone: +44 7738 881999

Email: nicolam@hutch-med.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place